Back

Severity of tricuspid regurgitation predicts risk of atrial fibrillation recurrence after pulmonary vein isolation

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Poster session on atrial fibrillation and supraventricular tachycardia Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Dimitrios Bismpos

Mary Hospital - Ruhr University hospital Bochum, Herne (Germany)

116 More presentations in this session

Presentation thumbnail
Left atrial strain measurement in patients with heart failure and atrial fibrillation compared to a control group
Doctor L. Herzer (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation after transcatheter tricuspid valve repair: rhythm control strategies and outcomes
Doctor J. Schipper (Cologne, DE)
Abstract
Presentation thumbnail
Left atrial strain defines functional and structural remodeling in patients with persistent atrial fibrillation
Doctor A. Grosse (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Cryoballoon ablation for atrial fibrillation in young adults: a propensity-score matching comparison with an older cohort
Presentation thumbnail
Procedural safety and outcome of additional left atrial posterior wall ablation using pulse field ablation for atrial fibrillation
Doctor J. Tay Cheong Kiat (Singapore, SG)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session on atrial fibrillation and supraventricular tachycardia

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Tricuspid regurgitation in atrial fibrillation: correlation to left atrial myopathy and improvement post ablation
thumbnail
Congress Presentation
Improvement in atrial functional and ventricular functional tricuspid regurgitation following catheter ablation or cardioversion of atrial fibrillation
thumbnail
Congress Presentation
Association between left atrial dysfunction and adverse outcomes after tricuspid valve surgery for atrial functional tricuspid regurgitation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources